185 related articles for article (PubMed ID: 27512852)
1. Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature review.
He G; Xiao X; Zou M; Zhang C; Xia S
Medicine (Baltimore); 2016 Aug; 95(32):e4401. PubMed ID: 27512852
[TBL] [Abstract][Full Text] [Related]
2. Phase II Study of High-Dose Pemetrexed Plus Cisplatin as First-Line Chemotherapy In the Treatment of Patients with Brain Metastases from Lung Adenocarcinoma.
He Q; Wang Y; Zou P; Wang Y; Xiu C; Zhang H; Chi N; Zou H; Xu J; Zhou S; Tao R
World Neurosurg; 2017 Mar; 99():758-762. PubMed ID: 27060518
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).
Barlesi F; Gervais R; Lena H; Hureaux J; Berard H; Paillotin D; Bota S; Monnet I; Chajara A; Robinet G
Ann Oncol; 2011 Nov; 22(11):2466-2470. PubMed ID: 21321089
[TBL] [Abstract][Full Text] [Related]
4. First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: A case report and review of the literature.
Zhang C; Kong FW; Wu WB; Zhang M; Yu GM; Wang X; Liu YY
Medicine (Baltimore); 2020 Sep; 99(36):e22128. PubMed ID: 32899099
[TBL] [Abstract][Full Text] [Related]
5. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.
Ortuzar W; Hanna N; Pennella E; Peng G; Langer C; Monberg M; Scagliotti G
Clin Lung Cancer; 2012 Jan; 13(1):24-30. PubMed ID: 21831719
[TBL] [Abstract][Full Text] [Related]
6. Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin
He Q; Bi X; Ren C; Wang Y; Zou P; Zhang H; Chi N; Xiu C; Wang Y; Tao R
Anticancer Res; 2017 Aug; 37(8):4711-4716. PubMed ID: 28739776
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial.
Dinglin XX; Huang Y; Liu H; Zeng YD; Hou X; Chen LK
J Neurooncol; 2013 May; 112(3):461-6. PubMed ID: 23420398
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.
Schmid-Bindert G; Gebbia V; Mayer F; Arriola E; Márquez-Medina D; Syrigos K; Biesma B; Leschinger MI; Frimodt-Moller B; Ripoche V; Myrand SP; Nguyen TS; Hozak RR; Zimmermann A; Visseren-Grul C; Schuette W
Lung Cancer; 2013 Sep; 81(3):428-434. PubMed ID: 23790468
[TBL] [Abstract][Full Text] [Related]
9. Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer.
Zhang Q; Cai XW; Zhu ZF; Yu W; Liu Q; Feng W; Xue MC; Fu XL
Anticancer Drugs; 2015 Apr; 26(4):456-63. PubMed ID: 25646743
[TBL] [Abstract][Full Text] [Related]
10. An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.
Novello S; Scagliotti G; de Castro G; Kiyik M; Kowalyszyn R; Deppermann KM; Arriola E; Bosquee L; Novosiadly RD; Nguyen TS; Forest A; Tang S; Kambhampati SRP; Cosaert J; Reck M
J Thorac Oncol; 2017 Feb; 12(2):383-389. PubMed ID: 27464970
[TBL] [Abstract][Full Text] [Related]
11. Frontline Systemic Therapy With Pemetrexed-Platinum in Nonsquamous Non-Small-Cell Lung Cancer With Asymptomatic Brain Metastases.
Alsidawi S; Chaudhary R; Karim NA
Am J Ther; 2017; 24(2):e111-e120. PubMed ID: 25153672
[TBL] [Abstract][Full Text] [Related]
12. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
[TBL] [Abstract][Full Text] [Related]
13. Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015.
Kozuki T; Nogami N; Kitajima H; Iwasawa S; Sakaida E; Takiguchi Y; Ikeda S; Yoshida M; Kato T; Miyamoto S; Sakamaki K; Shinkai T; Watanabe K
BMC Cancer; 2016 May; 16():306. PubMed ID: 27177035
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
[TBL] [Abstract][Full Text] [Related]
15. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
Yuan Y; Tan C; Li M; Shen H; Fang X; Hu Y; Ma S
World J Surg Oncol; 2012 Nov; 10():235. PubMed ID: 23134665
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.
Tsutani Y; Miyata Y; Masuda T; Fujitaka K; Doi M; Awaya Y; Kuyama S; Kitaguchi S; Ueda K; Hattori N; Okada M
BMC Cancer; 2018 Dec; 18(1):1231. PubMed ID: 30526545
[TBL] [Abstract][Full Text] [Related]
17. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.
Hellmann MD; Sturm I; Trnkova ZJ; Lettieri J; Diefenbach K; Rizvi NA; Gettinger SN
Clin Lung Cancer; 2015 Nov; 16(6):514-22. PubMed ID: 26003007
[TBL] [Abstract][Full Text] [Related]
18. A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
Wehler T; Thomas M; Schumann C; Bosch-Barrera J; Viñolas Segarra N; Dickgreber NJ; Dalhoff K; Sebastian M; Corral Jaime J; Alonso M; Hynes SM; Lin J; Hurt K; Bence Lin A; Calvo E; Paz-Ares L
Lung Cancer; 2017 Jun; 108():212-216. PubMed ID: 28625637
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer.
Gridelli C; Brodowicz T; Langer CJ; Peterson P; Islam M; Guba SC; Moore P; Visseren-Grul CM; Scagliotti G
Clin Lung Cancer; 2012 Sep; 13(5):340-6. PubMed ID: 22266043
[TBL] [Abstract][Full Text] [Related]
20. Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study.
Zhu W; Røe OD; Wu C; Li W; Guo R; Gu Y; Liu Y; Shu Y; Chen X
J Chemother; 2015 Aug; 27(4):221-6. PubMed ID: 25735792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
